Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Date:2/3/2010

ed during the STI period; however, the return of the virus was delayed. CD4+ T-cells and ZFN-modified T-cells were found to be stable and were observed in the GALT.  The data suggest that the modified cells were able to expand and were circulating and trafficking normally in the body.
  • Initiation of Phase 1 Clinical Trial to Evaluate ZFN-Therapeutic for the Treatment of Glioblastoma: Sangamo announced in January 2010 that the US Food and Drug Administration had reviewed and accepted an Investigational New Drug application to initiate this open-label, multi-dosing Phase 1 clinical trial. The Phase 1 glioblastoma trial is being initiated by Sangamo's collaborators at City of Hope and is designed to evaluate the safety and tolerability of a modified CD8+ cytotoxic T lymphocyte (CTL) product that has been made resistant to glucocorticoid steroids using Sangamo's ZFN-based technology.  The study will accrue subjects with recurrent/refractory malignant glioblastoma multiforme.  
  • Sangamo Scientists and Collaborators Receive Grant Funding from Several Sources to Develop ZFP Therapeutic Candidates:
    • Grand Challenges Explorations Grant from the Bill & Melinda Gates Foundation was awarded to Sangamo scientists in May 2009.  The grant of $100,000 supports an innovative global health research project conducted by Sangamo scientists and titled "Zinc Finger Nucleases for In Vivo Treatment of HIV Infection."
    • Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation was awarded to Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Resea
      '/>"/>

    SOURCE Sangamo BioSciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
    2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
    3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
    4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
    5. Sangamo Announces Pricing of Public Offering of Common Stock
    6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
    7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
    8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
    9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
    10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
    11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
    (Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
    (Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
    (Date:1/14/2014)... 14, 2014 Holloway America today announced ... material test reports (MTRs) for all pressure vessels and ... results is particularly important for equipment that must meet ... Library features search functionality that allows authorized users to ...
    Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
    ... 6, 2011 Spinal muscular atrophy (SMA) is the leading ... treatment other than supportive care. In the Proceedings of ... June 6), researchers at Children,s Hospital Boston show how loss ... and weakness, and suggest a promising approach to treating the ...
    ... 6, 2011 Oxford BioMedicaplc ("Oxford BioMedica" ... company, today announces that it has signed a research ... specialising in the development of engineered antibody fragments for ... in vivo diagnostic imaging agent using an ...
    ... Ganeden Biotech announced the sale of ... brands of probiotic dietary supplements to Schiff ...  Ganeden will also receive royalties on Schiff products containing ... rights to use Ganeden,s probiotic technology, GanedenBC30™, in the ...
    Cached Biology Technology:New Approaches Open up in Spinal Muscular Atrophy 2New Approaches Open up in Spinal Muscular Atrophy 3Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 2Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 3Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3
    (Date:4/23/2014)... of Exeter researcher has shed light on how an ... Australia,s remote outback have become reviled as pests and ... the Environment and Sustainability Institute at the University of ... in Australia, from their historic role helping to create ... unwelcome "invader." , The deserts of the Australian outback ...
    (Date:4/23/2014)... social mammals, ravens form different types of social relationships ... they also form strict dominance relations. From a cognitive ... key ability in daily social life ("knowing who is ... members have with each other sets the stage for ... of this study have been published in the scientific ...
    (Date:4/23/2014)... a 2 million Food Standards Agency (FSA) project to ... industry workers. , Norovirus outbreaks can rapidly affect ... of frozen strawberries infected 11,000 people in Germany, but ... which strains cause infection and which foods are the ... Researchers will produce data that will help the FSA ...
    Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Ravens understand the relations among others 2
    ... available in German . , A new ... could help to understand the positive effect of dietary restriction ... and mice) have shown that dietary restriction increases longevity, but ... the female fruit fly reproduces less frequently with a reduced ...
    ... discovery is challenging accepted thinking about amyloids the fibrous ... and may open up a potential new area for ... structures made up of proteins sometimes known as fibres - ... their formation which can damage cells and cause disease. ...
    ... Hausen and his co-workers discovered that specific types of human ... these pathogens cause cells to degenerate. It is known today ... Both proteins switch off different cellular control functions, thus promoting ... co-workers at DKFZ have now discovered another mechanism by which ...
    Cached Biology News:How nutrition affects healthy aging 2New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2
    ... the Quansys Biosciences Q-Plex Array is a ... for human, mouse, and rat research. The ... quantitative ELISA-based test where 4 distinct capture ... of a 96-well plate in a defined ...
    Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
    ... kit for 10 chips provides the chips ... with the Experion automated electrophoresis system. This ... x 520 microliters Pro260 gel, 45 microliters ... kD), 400 microliters Pro260 sample buffer, and ...
    ... The expertise that made the original Gene ... electroporation system available has been applied in the ... circuitry. The modular design of the Gene Pulser ... the accessory that has the widest range of ...
    Biology Products: